PA-824: Bicyclic Nitroimidazole for Drug-Resistant Tuberculosis Research

Executive Summary: PA-824 (CAS 187235-37-6) is a bicyclic nitroimidazole derivative exhibiting potent, dual-action bactericidal activity against both replicating and non-replicating Mycobacterium tuberculosis strains, including multidrug-resistant isolates (Ab Rahman et al., 2026). Its mechanism centers on inhibition of ketomycolate biosynthesis and enzymatic nitro-reduction, resulting in intracellular nitric oxide release for effective bactericidal effect (APExBIO). Quantitative studies report MIC values ranging from 0.015 μg/ml to 0.25 μg/ml, with an IC50 below 2.8 μM under aerobic conditions (APExBIO). PA-824 is supplied by APExBIO at ≥98% purity, with validated analytical and safety documentation. Recent evidence highlights its value in rational drug combination regimens to overcome resistance and sterilize persistent TB infections (Ab Rahman et al., 2026).

Biological Rationale

Tuberculosis (TB) remains a leading cause of death from infectious disease globally (Ab Rahman et al., 2026). The rise of multidrug-resistant (MDR) and extensively drug-resistant (XDR) M. tuberculosis strains necessitates novel therapeutic agents (APExBIO). PA-824, a bicyclic nitroimidazole, was developed to address resistance and latency by targeting both replicating and non-replicating mycobacteria. Its dual-action mechanism disrupts cell wall synthesis and impairs bacterial respiration, specifically benefiting research on persistent TB infection and drug-resistance mechanisms. The compound’s ability to release bactericidal nitric oxide intracellularly further distinguishes it from conventional anti-tuberculosis drugs.

Mechanism of Action of PA-824

PA-824 acts as a prodrug, requiring enzymatic activation by mycobacterial reductases. Upon nitro-reduction, it releases nitric oxide (NO) inside M. tuberculosis cells (Ab Rahman et al., 2026). This NO disrupts the electron transport chain, inhibiting both the cytochrome bcc:aa3 and bd oxidase branches. The resulting impairment of oxidative phosphorylation leads to ATP depletion and cell death, especially in non-replicating, antibiotic-tolerant populations. Simultaneously, PA-824 inhibits ketomycolate biosynthesis, a critical step in mycolic acid synthesis required for cell wall integrity. This dual mechanism contributes to its robust bactericidal profile. For a detailed discussion of mechanistic advances, see "PA-824: Mechanistic Insights and Future Frontiers in TB"—the present article updates with new in vitro synergy data and clinical translation perspectives.

Evidence & Benchmarks

• PA-824 exhibits minimum inhibitory concentrations (MIC) of 0.015–0.25 μg/ml against M. tuberculosis H37Rv under aerobic conditions (APExBIO).
• The compound retains activity against MDR and XDR strains, validated in both in vitro and murine infection models (Ab Rahman et al., 2026).
• PA-824’s IC50 for mycolic acid synthesis inhibition is less than 2.8 μM, determined by radiolabel incorporation assays (APExBIO).
• Synergistic bactericidal effects are observed when PA-824 is combined with terminal oxidase inhibitors such as telacebec (Q203), enhancing killing of both replicating and non-replicating bacilli (Ab Rahman et al., 2026).
• PA-824 is highly pure (≥98%), supplied with COA, HPLC, NMR, and MSDS documentation (APExBIO).

Applications, Limits & Misconceptions

PA-824 is widely used in preclinical tuberculosis research. Researchers employ it to study resistance mechanisms, drug synergy, and persistent infection models. Its high potency and dual mechanism make it a cornerstone in developing new anti-tuberculosis regimens. For more on PA-824’s translational applications and future clinical integration, see "PA-824 and the Next Frontier in Tuberculosis Research"—while that article focuses on innovation roadmaps, this piece emphasizes recent evidence and protocol precision.

Common Pitfalls or Misconceptions

• PA-824 is not active against non-mycobacterial pathogens; its spectrum is narrow and selective for M. tuberculosis complex (APExBIO).
• Inactive in aqueous or ethanol solvents: PA-824 is insoluble in water and ethanol; DMSO is required for stock preparation at ≥17.85 mg/mL (APExBIO).
• Not intended for clinical use: PA-824 from APExBIO is for research only; it is not approved for therapeutic administration (APExBIO).
• Short-term solution stability: Once in solution, PA-824 should be used promptly; storage at -20°C is required for the dry powder (APExBIO).
• Some prior reviews conflate PA-824 with delamanid or other nitroimidazoles; however, PA-824 has a distinct structure and activation pathway (Ab Rahman et al., 2026).

Workflow Integration & Parameters

For in vitro studies, PA-824 is typically dissolved in DMSO to a stock concentration of ≥17.85 mg/mL and diluted into culture media. It should be stored as a solid at -20°C for long-term stability. Working solutions are stable for short-term use (hours to days, depending on matrix and temperature). Researchers should confirm the absence of precipitation before use. For MIC determinations, recommended starting ranges are 0.001–1 μg/ml. High-purity batches from APExBIO ensure reproducibility and traceability (APExBIO). For a comparison of protocol variants and advanced mechanistic applications, see "PA-824: Next-Generation Bicyclic Nitroimidazole for Tuberculosis"—this article provides updated reference benchmarks and troubleshooting for laboratory use.

Conclusion & Outlook

PA-824, supplied by APExBIO, is a rigorously characterized bicyclic nitroimidazole with validated antimycobacterial activity and a unique dual mechanism. Its robust bactericidal profile and synergy with terminal oxidase inhibitors make it a key asset in tuberculosis drug research pipelines. Ongoing studies aim to further clarify optimal combination regimens and resistance suppression strategies (Ab Rahman et al., 2026). For authoritative product information and validated documentation, visit the PA-824 product page.